IgGs containing light chains of the α and k type and of all subclasses (IgG1-IgG4) from sera of patients with multiple sclerosis hydrolyze DNA

Journal of Molecular Recognition

Volumn 23, Issue 5, 2010, Pages 486-494

  Parkhomenko, Taisiya A ^a   Legostaeva, Galina A ^a   Doronin, Boris M ^b   Buneva, Valentina N ^a   Nevinsky, Georgy A ^a  

^a INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^b NOVOSIBIRSK STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Catalytic igg; Human blood antibodies; Hydrolysis of DNA; Multiple sclerosis

Indexed keywords

DNA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CHEMISTRY; FEMALE; GENETICS; HUMAN; HYDROLYSIS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS;

ADOLESCENT; ADULT; DNA; FEMALE; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 77956401252     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.1016     Document Type: Article

References (47)

1. Andrievskaya OA, Buneva VN, Baranovskii AG, Gal'vita AV, Benzo ES, Naumov VA, Nevinsky GA. 2002. Catalytic diversity of polyclonal RNA-hydrolyzing IgG antibodies from the sera of patients with systemic lupus erythematosus. Immunol. Lett. 81: 191-198.
2. Andrievskaya OA, Buneva VN, Naumov VA, Nevinsky GA. 2000. Catalytic heterogeneity of polyclonal RNA-hydrolyzing IgM from sera of patients with lupus erythematosus. Med. Sci. Monit. 6: 460-470.
3. Baranovskii AG, Ershova NA, Buneva VN, Kanyshkova TG, Mogelnitskii AS, Doronin BM, Boiko AN, Gusev EI, Favorova OO, Nevinsky GA. 2001. Catalytic heterogeneity of polyclonal DNA-hydrolyzing antibodies from the sera of patients with multiple sclerosis. Immunol. Lett. 76: 163-167.
4. Baranovskii AG, Kanyshkova TG, Mogelnitskii AS, Naumov VA, Buneva VN, Gusev EI, Favorova OO, Nevinsky GA. 1998. Polyclonal antibodies from blood and cerebrospinal fluid of patients with multiple sclerosis effectively hydrolyse DNA and RNA. Biochemistry (Mosc) 63: 1239-1248.
5. Belogurov AA, Kurkova IN, Friboulet A, Thomas D, Misikov VK, Zakharova MY, Suchkov SV, Kotov SV, Alehin AI, Avalle B, uslova E A, Morse H C 3rd, Gabibov A G, Ponamarenko N A. 2008. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J. Immunol. 180: 1258-1267.
6. Bonaci-Nikolic B, Jeremic I, Andrejevic S, Sefik-Bukilica M, Stojsavljevic N, Drulovic J. 2009. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus 18: 78-80.
7. Catalytic antibodies. 2005. Keinan EE (ed.). Wiley-VCH Verlag GmbH and Co. KgaA: 1-586.
8. Ciccarelli O, Bagnato F, Mainero C, Salvetti M, Paolillo A, Gasperini C, Bastianello S, Pozzilli C. 2000. Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis. Mult. Scler. 6: 137-139.
9. Cross AH, Trotter JL, Lyons J. 2001. B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol. 112: 1-14.
10. Fersht A. 1985. Enzyme Structure and Mechanism, (2nd edn). W.H. Freeman, Co: N.Y.
11. Gusev EI, Demina TL, Boiko AN. 1997. Multiple Sclerosis. Oil and Gas: Moscow.
12. Gololobov GV, Mikhalap SV, Starov AV, Kolesnikov AF, Gabibov AG. 1994. DNA-protein complexes. Natural targets for DNA-hydrolyzing antibodies. Appl. Biochem. Biotechnol. 47: 305-314.
13. Hemmer B, Archelos JJ, Hartung HP. 2002. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3: 291-301.
14. Kalaga R, Li L, O'Dell JR, Paul S. 1995. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J. Immunol. 155: 2695-2702.
15. Kanyshkova TG, Semenov DV, Khlimankov D, Buneva VN, Nevinsky GA. 1997. DNA-hydrolyzing activity of the light chain of IgG antibodies from milk of healthy human mothers. FEBS Lett 416: 23-26.
16. Kemeleva EA, Vasunina EA, Sinitsyna OI, Khomchenko AS, Gross MA, Kandalintseva NB, Prosenko AE, Nevinskii GA. 2008. New promising antioxidants based on 2,6-dimethylphenol. Bioorg. Khim. (Moscow) 34: 558-569.
17. Kozyr AV, Kolesnikov AV, Aleksandrova ES, Sashchenko LP, Gnuchev NV, Favorov PV, Kotelnikov MA, Iakhnina EI, Astsaturov IA, Prokaeva TB, Alekberova ZS, Suchkov SV, Gabibov AG. 1998. Autoantibodies to nuclear antigens: correlation between cytotoxicity and DNAhydrolyzing activity. Appl. Biochem. Biotechnol. 75: 45-61.
18. Krasnorutskii MA, Buneva VN, Nevinsky GA. 2008. Antibodies against DNA hydrolyze DNA and RNA. Biochemistry (Moscow) 73: 1547-1560.
19. Kubota T. 1977. Lessons from a monoclonal antibody to double-stranded DNA. J. Med. Dent. Sci. 44: 37-44.
20. Lacroix-Desmazes S, Bayry J, Kaveri SV, Hayon-Sonsino D, Thorenoor N, Charpentier J, Luyt CE, Mira JP, Nagaraja V, KazatchkineMD, Dhainaut JF, Mallet VO. 2005. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl. Acad. Sci. USA 102: 4109- 4113.
21. Nevinsky GA, Breusov AA, Baranovskii AG, Prints AV, Kanyshkova TG, Galvita AV, Buneva VN. 2001. Effect of different drugs on the level of DNA-hydrolyzing polyclonal IgG antibodies in sera of patients with Hashimoto's thyroiditis and nontoxic nodal goiter. Med. Sci. Monit. 7: 201-211.
22. Nevinsky GA, Buneva VN. 2002a. Human catalytic RNA- and DNAhydrolyzing antibodies. J. Immunol. Methods 269: 235-249.
23. Nevinsky GA, Buneva VN. 2003. Catalytic antibodies in healthy humans and patients with autoimmune and viral pathologies. J. Cell. Mol. Med. 7: 265-276.
24. Nevinsky GA, Buneva VN. 2005. Natural catalytic antibodies-abzymes. In Catalytic Antibodies, Keinan E (ed.). VCH-Wiley Press: Germany; 503-567.
25. Nevinsky GA, Favorova OO, Buneva VN. 2002b. Catalytic Antibodies: New Characters in the Protein Repertoire. Protein-Protein Interactions. A Molecular Cloning Manual. Cold Spring Harbor: NY; 523-534.
26. Nevinsky GA, Kanyshkova TG, Semenov DV, Vlassov AV, Gal'vita AV, Buneva VN. 2000. Secretory immunoglobulin A from healthy human mothers' milk catalyzes nucleic acid hydrolysis. Appl. Biochem. Biotechnol. 83: 115-129.
27. Neustroev KN, Ivanen DR, Kulminskaya AA, Brumer IH, Saveliev AN, Nevinsky GA. 2003. Amylolytic activity, catalytic properties of IgM, IgG antibodies from patients with systemic lupus erythematosus. Hum. Antibodies 12: 31-34.
28. Niehaus A, Shi J, Grzenkowski M, Diers-Fenger M, Archelos J, Hartung HP, Toyka K, Bruck W, Trotter J. 2000. Patients with active relapsing- remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann. Neurol 48: 362-371.
29. Nishi Y. 2002. Evolution of catalytic antibody repertoire in autoimmune mice. J. Immunol. Method. 269: 213-233.
30. O'Connor KC, Bar-Or A, Hafler DA. 2001. Neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J. Clin. Immunol. 21: 81-92.
31. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. 1989. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244: 1158-1162.
32. Poser CM. 1984. The Diagnosis of Multiple Sclerosis. Thieme-Stratton: NY.
33. Polosukhina DI, Buneva VN, Doronin BM, Tyshkevich OB, Boiko AN, Gusev EI, Favorova OO, Nevinsky GA. 2005. Hydrolysis of myelin basic protein by IgM and IgA antibodies from the sera of patients with multiple sclerosis. Med. Sci. Monit. 11: BR266-BR272.
34. Polosukhina DI, Kanyshkova TG, Doronin BM, Tyshkevich OB, Buneva VN, Boiko AN, Gusev EI, Favorova OO, Nevinsky GA. 2004. Hydrolysis of myelin basic protein by polyclonal catalytic IgGs from the sera of patients with multiple sclerosis. J. Cell Mol. Med. 8: 359-368.
35. Polosukhina DI, Kanyshkova TG, Doronin BM, Tyshkevich OB, Buneva VN, Boiko AN, Gusev EI, Favorova OO, Nevinsky GA. 2006. Metaldependent hydrolysis of myelin basic protein by IgGs from the sera of patients with multiple sclerosis. Immunol. Lett 103: 75-81.
36. Ponamorenko NA, Durova OM, Vorobiev II, Belogurov AA, Kurkova IN, Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM, Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, Thomas D, Friboulet A, Gabibiv AG. 2006. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc. Natl. Acad. Sci USA 103: 281-286.
37. Pelletier J, Ali Cherif A. 2000. ''Multiple sclerosis plus'': leukoencephalopathies at the frontiers of internal medicine. Rev. Med. Interne. 21: 1104-1113.
38. Practical work in microbiology. 2005. Netrusov AI (ed.). Academa: Moscow; 1-597.
39. Saveliev AN, Ivanen DR, Kulminskaya AA, Ershova NA, Kanyshkova TG, Buneva VN, Mogelnitskii AS, Doronin BM, Favorova OO, Nevinsky GA, Neustroev KN. 2003. Amylolytic activity of IgM and IgG antibodies from patients with multiple sclerosis. Immunol. Lett. 86: 291-297.
40. Shoenfeld Y, Ben-Yehuda O, Messinger Y, Bentwitch Z, Rauch J, Isenberg DI, Gadoth N. 1988. Autoimmune diseases other than lupus share common anti-DNA idiotypes. Immunol. Lett. 17: 285-291.
41. Shoenfeld Y, Teplizki HA, Mendlovic S, Blank M, Mozes E, Isenberg DA. 1989. The role of the human anti-DNA idiotype 16/6 in autoimmunity. Clin. Immunol. Immunopathol. 51: 313-325.
42. Sinohara H, Matsuura K. 2000. Does catalytic activity of Bence-Jones proteins contribute to the pathogenesis of multiple myeloma? Appl. Biochem. Biotechnol. 83: 85-94.
43. Speciale L, Saresella M, Caputo D, Ruzzante S, Mancuso R, Calvo MG, Guerini FR, Ferrante P. 2000. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J. Neurovirol. 6 (Suppl 2): S57-S61.
44. Steinman L. 2001. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2: 2762-2764.
45. Tawfik DS, Chap R, Green BS, Sela M, Eshhar Z. 2002. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity? Proc. Natl. Acad. Sci. USA 92: 2145-2149.
46. Theodoridou A, Settas L. 2008. Demyelination in rheumatic diseases. Postgrad. Med. J 84(989): 127-132.
47. Williamson RA, Burgoon MP, Owens GP, Ghausi O, Leclerc E, Firme L, Carlson S, Corboy J, Parren PW, Sanna PP, Gilden DH, Burton DR. 2001. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl. Acad. Sci. USA 98: 1793-1798.